In October 2021, Dr. Liu Cheng, President of Affinity Biopharma, was invited to participate in the 9th Healthcare and Life Sciences Leadership Summit held by China Renaissance. At this summit, top scientists, corporate CEOs and investors in the fields of healthcare and life science have joined to discuss the future development directions in the epidemic and post-epidemic era.

Dr. Liu Cheng has taken part in the Innovative Drug Roundtable section under the topic "Platform Innovation Empowers Drug R&D and Transformation", and discussed the key points of independently building innovative platform, the strategy of platform-derived products, the focus of solving clinical unmet needs, and R&D challenges and trends of platform-based innovative drugs.

The guest speakers in this roundtable "Platform Innovation Empowers Drug R&D and Transformation " include:

Liu Cheng, Founder, President, and CSO of Affinity Biopharma

Cang Yong, Founder of Degron Therapeutics

Cheng Wei, Co-Founder and CEO of ERai Therapeutics

Jin Zhaoyu, Founder and CEO of FutureGen Biopharm

Yu Guoliang, Chairman and CEO of Apollomics

Zhang Jian, Co-founder of NUTSHELL Biotechnology

Yu Rui, Managing Director of Oceanpine Capital